CLS vs NVDA

Celestica Inc. exhibits a stark divergence between its explosive growth metrics and its deterministic health indicators, highlighted by a weak Piotroski F-Score of 3/9. While the company delivers exceptional revenue (43.6%) and earnings (77.7%) growth with a consistent track record of beats, the current price of $410.21 represents a massive premium over both the Graham Number ($55.82) and the growth-based Intrinsic Value ($211.81). The combination of bearish insider selling and a weak technical trend suggests the stock may be overextended despite strong analyst sentiment. Consequently, the valuation risk currently outweighs the growth momentum.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.